Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02609685 · ClinicalTrials.gov registry record · NA
Active Surveillance of Papillary Thyroid Microcarcinoma
A NA study of Papillary Thyroid Microcarcinoma, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 216
- Enrollment target
- 1
- Study location
NCT02609685 is a NA study of Papillary Thyroid Microcarcinoma that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 216 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02609685, a NA study of Papillary Thyroid Microcarcinoma, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 216 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma will be eligible for the study.
Conditions Studied
Interventions
- OTHER Active Surveillance
Study Locations (1)
California
- Cedars-Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 216 participants |
| Start Date | 2016-05-13 |
| Est. Completion | 2030-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02609685
The ClinicalTrials.gov registry entry for NCT02609685 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 216 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Papillary Thyroid Microcarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Active Surveillance is the first listed.
NCT02609685 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT02609685 about?
NCT02609685 is a clinical study titled "Active Surveillance of Papillary Thyroid Microcarcinoma". The purpose of this study is to better understand the outcomes of active surveillance (observation) instead of immediate surgery, which is the current standard of care for papillary thyroid microcarcinoma (PTMC). Patients with a 1.5 cm or smaller thyroid nodule(s) with papillary thyroid carcinoma wi...
What is the current status of trial NCT02609685?
This trial is currently recruiting. It is a NA study. The enrollment target is 216 participants. The study started on 2016-05-13. Estimated completion is 2030-12.
What conditions does trial NCT02609685 study?
This clinical trial studies the following conditions: Papillary Thyroid Microcarcinoma.
What interventions are being tested in trial NCT02609685?
The interventions under investigation include: Active Surveillance (OTHER).
Who is sponsoring clinical trial NCT02609685?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02609685 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papillary Thyroid Microcarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.